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Genetically engineered pre-
microRNA-34a prodrug suppresses 
orthotopic osteosarcoma xenograft 
tumor growth via the induction of 
apoptosis and cell cycle arrest
Yong Zhao1,2, Mei-Juan Tu2, Wei-Peng Wang2, Jing-Xin Qiu3, Ai-Xi Yu1 & Ai-Ming Yu2
Osteosarcoma (OS) is the most common primary malignant bone tumor in children, and microRNA-
34a (miR-34a) replacement therapy represents a new treatment strategy. This study was to define the 
effectiveness and safety profiles of a novel bioengineered miR-34a prodrug in orthotopic OS xenograft 
tumor mouse model. Highly purified pre-miR-34a prodrug significantly inhibited the proliferation of 
human 143B and MG-63 cells in a dose dependent manner and to much greater degrees than controls, 
which was attributed to induction of apoptosis and G2 cell cycle arrest. Inhibition of OS cell growth and 
invasion were associated with release of high levels of mature miR-34a from pre-miR-34a prodrug and 
consequently reduction of protein levels of many miR-34a target genes including SIRT1, BCL2, c-MET, 
and CDK6. Furthermore, intravenous administration of in vivo-jetPEI formulated miR-34a prodrug 
significantly reduced OS tumor growth in orthotopic xenograft mouse models. In addition, mouse 
blood chemistry profiles indicated that therapeutic doses of bioengineered miR-34a prodrug were well 
tolerated in these animals. The results demonstrated that bioengineered miR-34a prodrug was effective 
to control OS tumor growth which involved the induction of apoptosis and cell cycle arrest, supporting 
the development of bioengineered RNAs as a novel class of large molecule therapeutic agents.
Osteosarcoma (OS) is the most common primary bone cancer consisting of malignant tumor cells that directly 
leads to osteoid or immature bone. OS accounts for approximately 60% of malignant bone tumors in children 
and young adults, and OS remains a leading cause of cancer-related death among adolescents1–3. OS is not only 
locally destructive but also highly pulmonary metastatic4–6. While there are some improved options including the 
combination of surgery and chemotherapy for the treatment of OS, 20–40% of OS patients are unable to survive 
over five years and most of them would eventually die of pulmonary metastases. Therefore, there is a clear need 
for developing more effective therapeutic strategies to treat OS. Nevertheless, current efforts are limited to the 
evaluation of small molecule drugs and protein therapeutics7.
MicroRNAs (miRNAs or miRs) are a large family of genomically encoded regulatory RNA molecules that may 
control various cancer cellular processes through the regulation of target gene expression8–10 and thus open the 
avenues to develop miRNA based therapy10–12. Recent studies have revealed that some miRNAs are dysregulated 
in OS tumor tissues and cancer cell lines, compared with normal bone tissues and osteoblastic cell lines, respec-
tively13. Among them, miR-34a is significantly downregulated in OS tumors, and a lower miR-34a expression 
is also linked to a remarkably lower disease-free survival rate14–16. Indeed miR-34a acts as a tumor suppressor 
through the downregulation of many target genes in cancer cells, including NAD-dependent deacetylase sirtuin-1 
(SIRT1), hepatocyte growth factor receptor c-MET, cyclin-dependent kinase 6 (CDK6), B-cell lymphoma 2 
(BCL2), and cell surface glycoprotein CD4417–21. In addition, ectopic expression of miR-34a inhibits the prolif-
eration and tumorigenesis of OS cells in vitro and in vivo, and reintroduction of chemically synthesized miR-34a 
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mimics suppresses OS cell proliferation in vitro15,16,22,23. However, there is no report yet on the effectiveness of 
systemic administration of a miR-34a agent for the control of OS tumor progression in a whole body system.
In an effort to develop miRNA based therapy, we have established recently a novel approach to bioengineering 
of large quantities, more affordable pre-microRNA agents24–28. Different from synthetic miRNA agents (e.g., miR-
34a mimics or pre-miR-34a)11,16,19,29,30, bioengineered RNA agents (BERAs) are produced and folded in the cells 
and may better capture the function and safety properties of natural RNAs and represent a novel class of large 
molecule agents for research and development31. Indeed genetically engineered miR-34a prodrug is selectively 
processed to mature miR-34a in human lung carcinoma cells, and consequently inhibits cancer cell proliferation 
in vitro. In addition, intratumoral injection of biological miR-34a prodrug sharply reduces the growth of sub-
cutaneously implanted xenograft tumors in vivo24. In this study, we aimed to define the effectiveness and safety 
profiles of systemic administration of bioengineered miR-34a prodrug in a more clinically relevant orthotopic OS 
xenograft tumor mouse model in vivo. In addition, the mechanistic actions of biological miR-34a prodrug in the 
control of OS were delineated in human OS cells in vitro.
Results
Osteosarcoma cell proliferation is inhibited by genetically engineered miR-34a prodrug. We 
first employed MTT assay to assess the antiproliferative activity of miR-34a prodrug against human OS 143B 
and MG-63 cells. The results showed that tRNA/mir-34a suppressed osteosarcoma cell proliferation in a dose 
dependent manner, and to a significantly greater degree than the control tRNA/MSA (P < 0.001, two-way 
ANOVA; Fig. 1A). The greater effect of miR-34a prodrug on cell proliferation than the control tRNA/MSA was 
further manifested by lower EC50 and Bottom (greater inhibition) values, as compared with the control treat-
ment (P < 0.05, one-way ANOVA; Fig. 1B). In addition, 143B cells were more sensitive to miR-34a prodrug than 
MG-63 cells (Fig. 1A), which was also indicated by the lower Bottom value (Fig. 1B). As such, and given the fact 
that the morphology of MG-63 cells is rather more fibroblastic and 143B cells are highly tumorigenic and met-
astatic28,32–34, the following in vitro mechanistic and in vivo therapeutic studies were conducted with 143B cells.
BERA miR-34a prodrug is processed to mature miR-34a in OS cells and reduces the protein 
expression of many miR-34a target genes. To understand the molecular mechanisms underlying the 
antiproliferative effect of bioengineered miR-34a prodrug against OS 143B cells, we quantitated mature miR-34a 
levels using selective stem-loop reverse transcription RT-qPCR assay and determined the protein levels of several 
miR-34a targeted oncogenes using Western blot analysis. Our data revealed a 190-fold higher mature miR-34a 
level in the cells treated with tRNA/mir-34a than tRNA/MSA or vehicle (Fig. 2A), consistent with our recent 
Figure 1. Inhibition of osteosarcoma cancer cell proliferation by genetically engineered miR-34a prodrug. 
(A) Dose-response curves for the effects of tRNA/miR-34a versus control tRNA/MSA on 143B and MG-63 cell 
viability. (B) The estimated pharmacodynamic parameters. Cell viability was determined using MTT assay at 
72 h post-treatment, which was suppressed to a significantly (P < 0.001, two-way ANOVA) greater degree by 
tRNA/mir-34a than tRNA/MSA. This is also indicated by a lower EC50 and Bottom value (P < 0.05, one-way 
ANOVA). Values are mean ± SD of triplicate treatments.
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findings from unbiased RNA sequencing and targeted RT-qPCR studies in lung carcinoma cells24. Furthermore, 
immunoblot analyses showed that 143 cells treated with tRNA/mir-34a had lower protein levels of several miR-
34a target genes including SIRT1, BCL2, CDK6, and c-MET (Fig. 2B). These results indicate that the antiprolif-
erative activity of bioengineered miR-34a prodrug (Fig. 1) may be attributable to the processed mature miR-34a 
and consequently the suppressed target oncogene expression (Fig. 2).
Bioengineered miR-34a prodrug induces apoptosis in osteosarcoma 143B cells. To evaluate 
whether the inhibition of 143B cell proliferation by miR-34a prodrug involves apoptosis mechanism, we exam-
ined apoptotic profiles using Annexin V/propidium iodide flow cytometric analysis (Fig. 3A). While tRNA/
mir-34a treatment led to an increase in the number of necrotic cells than the vehicle control, the effect did not 
differ between BERA tRNA/mir-34 and tRNA/MSA treatments (Fig. 3B). In contrast, tRNA/mir-34a signifi-
cantly enhanced late apoptosis to much greater degrees, compared with the control tRNA/MSA or vehicle treat-
ment (P < 0.001, two-way ANOVA; Fig. 3B). Thus we further investigated an apoptosis biomarker, Caspase-3, 
using immunofluorescence assay (Fig. 3C), and quantitatively compared the number of Caspase-3-positive cells 
between different treatment groups (Fig. 3D). Our data showed that there was a 5-fold increase in Caspase-
3-positive cells in tRNA/mir-34a treatment group, as compared with tRNA/MSA or vehicle treatment (P < 0.01, 
one-way ANOVA; Fig. 3B). Together, the results suggest that miR-34a prodrug largely enhances apoptosis of 
osteosarcoma 143B cells.
BERA miR-34a prodrug causes a G2 cell cycle arrest in osteosarcoma 143B cells. To assess 
whether cell cycle progress is arrested at certain checkpoints by miR-34a prodrug, we investigated the cell cycle 
profiles with flow cytometric analysis after staining for DNA content (Fig. 4A). Compared with tRNA/MSA or 
vehicle treatment, tRNA/mir-34a resulted in a 3-fold higher accumulation of 143B cells in G2 phase (P < 0.001, 
two-way ANOVA; Fig. 4B). The G2 phase arrest was also accompanied with a reduction of cells in G1 and S 
phases. Likewise, we employed immunofluorescence assay to examine the cell proliferation biomarker Ki-67, a 
nuclear antigen expressed in all active phases of cell cycle. Consistent with the above MTT study (Fig. 1A), tRNA/
mir-34a sharply reduced the number of live 143B cells, as indicated by nuclear staining with DAPI (Fig. 4C). 
Interestingly, nuclear Ki-67 contents in the cells treated with tRNA/mir-34a were significantly lower than tRNA/
MSA or vehicle (P < 0.05, one-way ANOVA; Fig. 4D), demonstrating a compromised proliferation ability. 
Moreover, the Ki-67 was almost absent in a large portion of tRNA/mir-34a-treated 143B cells (Fig. 4C; high-
lighted in the red rectangle), which may indicate that these cells were undergoing cell cycle arrest.
Biological miR-34a prodrug suppresses the invasion ability of osteosarcoma 143B cells. We 
further investigated the impact of miR-34a prodrug on invasion capability of human OS 143B cells, since cancer 
cell invasion is a critical process for tumor progression and metastasis. Invasion of 143B cells under different 
treatments was determined by the Matrigel invasion assay, and invasive ability was indicated by the number of 
cells presented on the lower side of the insert chamber (Fig. 5). Our data revealed that the invasion ability of 
143B cells treated with tRNA/mir-34a was 60–70% lower, compared to cells treated with tRNA/MSA and vehicle 
(P < 0.001, one-way ANOVA; Fig. 5B). The results suggest that miR-34a prodrug is able to reduce the invasion 
ability of human OS 143B cells.
Bioengineered miR-34a prodrug is effective to suppress osteosarcoma growth in an orthotopic 
xenograft tumor mouse model. We thus developed an orthotopic OS xenograft tumor mouse model 
through subperiosteal injection of 143B cells into immunodeficient mice, and evaluated the effectiveness of BERA 
Figure 2. Genetically engineered miR-34a prodrug was processed to mature miR-34a in human osteosarcoma 
143B cells (A), which consequently reduced the protein expression of miR-34a target genes including SIRT1, 
BCL2, CDK6 and c-MET (B). Cells were harvested at 72 h after treatment with tRNA/mir-34a or control tRNA/
MSA, or vehicle. Mature miR-34a levels were quantitated by selective stem-loop reverse transcription RT-qPCR 
assay, and normalized to U6 levels. Protein was detected by Western blot analyses, and GAPDH was used as a 
loading control. Values are mean ± SD of triplicate treatments. *** P < 0.001 (one-way ANOVA), as compared 
with tRNA/MSA or vehicle control treatment.
www.nature.com/scientificreports/
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miR-34a prodrug to control tumor growth in vivo. All mice inoculated with 143B cells developed primary tum-
ors, which were readily visualized and reached to 50–110 mm3 in 8–10 days. We treated these mice intravenously 
with in vivo-jetPEI-formulated tRNA/mir-34a for 2 weeks (Fig. 6A). Separate groups of animals bearing 143B 
xenograft tumors were treated with the same doses of in vivo-jetPEI-formulated tRNA/MSA or vehicle as con-
trols. Compared with the vehicle or the same doses of tRNA/MSA, tRNA/mir-34a treatment showed a remark-
able suppression of the outgrowth of viable tumors (P < 0.001, two-way ANOVA; Fig. 6B). Dissected orthotopic 
xenograft tumors from tRNA/mir-34a-treated mice were indeed much smaller (Fig. 6C) than tRNA/MSA and 
vehicle treatment groups, which were further confirmed by histological examination (data not shown). These 
results indicate that intravenous administration of biological miR-34a prodrug is effective to control orthotopic 
OS xenograft tumor progression in vivo.
Therapeutic doses of miR-34a prodrug are well tolerated in xenograft tumor mice. In addi-
tion, therapeutic doses of miR-34a prodrug had no significant effect on mouse body weights, compared with 
either vehicle or tRNA/MSA treatments (data not shown). Mouse blood chemistry profiles including alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), total protein, albumin, total bilirubin, alkaline phos-
phatase (ALP), blood urea nitrogen (BUN), and creatinine were further determined and compared between 
different treatment groups. The data showed that none of these blood biomarkers was significantly altered by 
biological tRNA/mir-34a, as compared with vehicle or tRNA/MSA treatments (Fig. 7), suggesting the absence of 
Figure 3. Bioengineered miR-34a prodrug enhanced the apoptosis of osteosarcoma 143B cells.  
(A) Comparison of flow cytometry histograms of Annexin V/propidium iodide stained cells, following the 
treatments with tRNA/mir-34a, control tRNA/MSA and vehicle. (B) Comparison of the percent of apoptotic 
cells with different treatments. (C) Confocal immunofluorescent analyses of Caspase-3 biomarker in 143B cells. 
(D) The number of Caspase-3-positive cells were compared for different treatments. Cells were treated with 
4 nM tRNA/mir-34a, tRNA/MSA or the vehicle for 72 h, and apoptosis was assessed by Annexin V/propidium 
iodide flow cytometric analysis. A separate batch of treated cells were fixed with 10% formalin, stained with 
Caspase-3 antibody, and counterstained with DAPI. Caspase-3 fluorescence and DAPI-stained nuclei images 
were acquired with a confocal microscope. Values are mean ± SD of triplicate treatments. * P < 0.05, ** P < 0.01, 
and ***P < 0.001 (two- or one-way ANOVA).
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liver or kidney toxicity. These results indicate that therapeutic doses of miR-34a prodrug are well tolerated in the 
orthotopic OS xenograft tumor mouse models during the treatment.
Discussion
Evaluation of miRNA based therapies in animal models and human subjects relies on the access to large quan-
tities of miRNA agents. The novel BERA miR-34a prodrug examined in current study is a natural RNA agent 
produced and folded within the cells24,25, which are distinguished from synthetic miR-34a mimics and precur-
sors16,19,29,30,35 consisting of extensive chemical modifications on the ribose and phosphate bone that may alter the 
tertiary structure, physicochemical properties, biological/pharmacological activity, and/or safety profiles31. In 
addition, bioengineered miR-34a prodrug is literally large molecule RNA agent, in contrast to viral or non-viral 
vector-based miR-34a expression plasmids/systems36 that are rather DNA materials and may complicate these 
RNA-based processes. Therefore, bioengineered pre-miRNAs such as miR-34a prodrug investigated for OS in 
current study may represent a new class of large molecules for therapy.
Investigation of new therapeutics also requires the use of more clinical relevant models. Many human OS cell 
lines have been critically assessed for relevance to the characteristics of primary OS in patients32,37. The 143B cells 
carrying a p53 mutant and showing high-level expression of p53 were consistently identified to be highly tumor-
igenic and metastatic, and thus it is widely used to study OS cancer biology and examine new therapies32–34,38–41. 
By contrast, the MG-63 cells were found to be tumorigenic in mice by some studies15,42,43 but unable to produce 
xenograft tumors by other studies32, whose morphology is actually more fibroblastic and consists of wild-type 
p53 and lower level of p53 expression. Our results showed that 143B cells were more sensitive to miR-34a prodrug 
than MG-63 cells in vitro, which may be related to the involvement of miR-34a in the p53 pathways17,23,44. Indeed 
Figure 4. Bioengineered miR-34a prodrug induced a G2 cell cycle arrest in osteosarcoma 143B cells. 
(A) Comparison of flow cytometry histograms of propidium iodide-stained cells treated with vehicle, tRNA/
MSA and tRNA/mir-34a. (B) Comparison of each cell cycle (G1, S and G2) phase percentage. (C) Images of 
biomarker Ki-67 fluorescence in 143B cells with different treatments. (D) Nuclear Ki-67 fluorescence intensities 
were compared for different treatments, which were quantitated with ImageJ software and normalized to the 
numbers of cells in corresponding groups. Cells were treated with 4 nM tRNA/mir-34a or tRNA/MSA, or the 
vehicle for 72 h, stained with propidium iodide, and flow cytometric analyses were conducted to define cell cycle 
phases. A different batch of treated cells were fixed with 10% formalin, stained with Alexa Fluor dye-labeled 
Ki-67 antibody, and counterstained with DAPI. Ki-67 fluorescence and DAPI-stained nuclei images were 
acquired with a confocal microscope. Values are mean ± SD of triplicate treatments. * P < 0.05, ** P < 0.01, and 
*** P < 0.001 (two- or one-way ANOVA), as compared with either tRNA/MSA or vehicle treatment.
www.nature.com/scientificreports/
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all mice inoculated with 143B cells in our study developed xenograft tumors for drug efficacy and safety tests 
in vivo. Nevertheless, none of the mice showed any lung metastases, which may be due to an early termination 
(22 days after inoculation) and injection of less cells (1.5 × 106 of 143 cells per mouse) than previous studies 
(1 month after inoculation and 2.0 × 106 of 143 cells per mouse, respectively)32.
Using the orthotopic 143B xenograft OS tumor mouse model and genetically engineered miR-34a prodrug, 
this study revealed that miR-34a replacement therapy was indeed effective to reduce the growth of OS xenograft 
tumors, supporting the concept to develop novel biological miRNA therapeutics31. Current study is different 
from our recent study in which mice bearing subcutaneous xenograft lung tumors were treated intratumorally 
with recombinant miR-34a24. In this regard, the present study on systemic administration of miR-34a prodrug 
to orthotopic xenograft tumor mouse is more relevant to clinical applications. Additionally, therapeutic doses of 
biological miR-34a prodrug were well tolerated in these tumor mice, as manifested by the absence of change in 
blood chemistry profiles and signs of any stress (e.g., hunched posture and labored movement). This finding is 
also different from our recent study on the safety profiles of an acute, high dose of bioengineered miR-34a prod-
rug in immunocompetent mice24.
Figure 5. Bioengineered miR-34a prodrug significantly inhibited the invasion ability of osteosarcoma 
143B cells. Cell images (A; 200× magnification) were acquired with a Olympus IX2-UCB microscope, and 
invasion capacities were compared for different treatments (B). Cells were treated with 4 nM tRNA/mir-34a or 
tRNA/MSA, or vehicle for 72 h, subjected to Matrigel invasion assay for 24 h, fixed with 10% formalin, and then 
stained with 0.1% crystal violet. Values are mean ± SD of six treatments. *** P < 0.001 (one-way ANOVA), as 
compared with tRNA/MSA or vehicle treatment.
Figure 6. Genetically engineered miR-34a prodrug significantly suppressed tumor growth in an orthotopic 
osteosarcoma xenograft tumor mouse model. (A) Timeline of osteosarcoma cell inoculation and drug 
treatment. (B) Xenograft tumor growth was significantly (P < 0.001, two-way ANOVA) reduced in mice treated 
with tRNA/miR-34a than the control tRNA/MSA or vehicle. (C) Visual comparison of the dissected orthotopic 
tumor tissues. Values are mean ± SD (N = 6 in each group).
www.nature.com/scientificreports/
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Consistent with our recent observations in human lung adenocarcinoma cells24, the present study also showed 
that tRNA-carried miR-34a prodrug was selectively processed to high levels of mature miR-34a in OS cells. The 
mechanistic actions of miR-34a were supported by the selective suppression of protein expression levels of a 
number of well-defined miR-34a target genes including SIRT1, BCL2, CDK6, and c-MET that are critical for 
cancer cellular processes, such as cell cycle, apoptosis and invasion17–20. Therefore, the reduction of miR-34a target 
genes also provides a molecular explanation for the effects of miR-34a prodrug in inhibiting OS cell proliferation, 
enhancing apoptosis, inducing cell cycle arrest, and suppressing invasion ability in cells in vitro, which together 
offers a good explanation for the effectiveness of miR-34a in suppressing OS xenograft tumor growth in mice 
in vivo.
It is noteworthy that the tRNA scaffold itself, at higher concentrations, was able to inhibit the proliferation 
of OS cells (current study) as well as lung and liver cancer cells24, whereas to a much lower degree than the 
tRNA/mir-34a. The genomically-derived tRNA species are eventually processed to tRNA fragments (tRFs) within 
mammalian cells, which may be induced under hypoxic stress45–48. Some tRFs were shown to inhibit cancer cell 
proliferation, angiogenesis or metastasis45,48,49. The antiproliferative activity of this methionyl tRNA (tRNA/MSA; 
Fig. 1) is attributable to the induction of apoptosis (Fig. 3), which is also processed to various tRFs in human 
carcinoma cells24,25. A very recent report showed that several tRF species were effective to suppress the tumori-
genesis of breast cancer cells via binding to oncogenic RNA-binding protein, YBX-1, to displace pro-oncogenic 
transcripts48. However, the present study showed that lower doses of intravenously administered tRNA/MSA did 
not affect orthotopic OS xenograft tumor progression (Fig. 6), consistent with recent observations from subcuta-
neous lung and liver xenograft tumor mouse models24.
In summary, the present study demonstrated that systemic administration of therapeutic doses of highly 
purified, genetically engineered miR-34a prodrug was effective to suppress tumor growth and well tolerated in 
the orthotopic osteosarcoma xenograft tumor mouse models. Mechanistically, BERA miR-34a prodrug was pro-
cessed to mature miR-34a in human osteosarcoma cells and subsequently reduced the protein expression of many 
miR-34a target genes, enhanced apoptosis, induced cell cycle arrest, and inhibited cell invasion capability. These 
findings support the miR-34a replacement therapy strategy for the treatment of osteosarcoma and most impor-
tantly, the development of bioengineered miRNA agents as novel large molecule therapeutics.
Methods
Human cell lines. The human OS cell lines 143B (CRL-8303) and MG-63 (CRL-1543) were purchased from 
American Type Culture Collection (Manassas, VA). Both 143B and MG-63 cells were cultured in RPMI 1640 
Figure 7. Administration of therapeutic doses of bioengineered miR-34a prodrug had no significant 
effects on mouse blood chemistry profiles including alanine transaminase (ALT), aspartate transaminase 
(AST), total protein, albumin, total bilirubin, alkaline phosphatase (ALP), blood urea nitrogen (BUN), and 
creatinine levels, as compared to vehicle or tRNA/MSA treatment. The ranges of individual markers (derived 
from BALB/c mice; Comparative Pathology Laboratory at UC-Davis) were labeled as a reference. Values are 
mean ± SD (N = 3 in each group).
www.nature.com/scientificreports/
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medium (GE Healthcare Bio-Sciences, Pittsburgh, PA) supplemented with 10% fetal bovine serum (GBICO BRL, 
Rockville, MD), at 37 °C in a humidified atmosphere containing 5% CO2. Cells in the logarithmic growth phase 
were used for experiments.
Bioengineering miR-34a prodrug. Expression and purification of biological miR-34a prodrug (tRNA/
mir-34a or sephadex aptamer tagged methionyl tRNA fusion pre-miR-34a) and control tRNA scaffold (tRNA/
MSA or sephadex aptamer tagged methionyl tRNA) were conducted as we described very recently24–26. The purity 
was verified by denaturing urea (8 M) polyacrylamide (8%) gel electrophoresis (PAGE) and high performance 
liquid chromatography (HPLC) analyses24, and highly purified (over 98% by HPLC) recombinant noncoding 
RNAs (ncRNAs) were used in this study.
MTT assay. The effects of bioengineered miR-34a prodrug on the proliferation of 143B and MG-63 OS cells 
were determined using MTT assay, as described24–26. Briefly, cells were seeded in 96-well plates (Corning, NY) at 
5,000 cells per well in 200 μ l medium. 24 h later, cells were treated with various concentrations (0, 0.3, 1.0, 3.0, 5.0, 
10, 30, and 100 nM) of tRNA/mir-34a or tRNA/MSA using Lipofectamine 2000 (Thermo Fisher Scientific Inc.) for 
72 h. Cell viability was then determined using a MTT Cell Proliferation Assay kit (Thermo Fisher Scientific Inc.). 
Cells were treated in triplicate and assayed separately. Data were fit into a normalized inhibitory dose-response 
model with variable slope (Y = Bottom + (100-Bottom)/(1 + 10^((LogEC50-X)* HillSlope); GraphPad Prism, San 
Diego, CA) for the estimation of EC50, Hill slope, and Bottom values.
RNA isolation and reverse transcription quantitative real-time PCR (RT-qPCR). OS 
143B cells were seeded in six-well plates (0.1 × 106 cells per well). 24 h later, cells were transfected with 
10 nM tRNA/mir-34a or tRNA/MSA, or vehicle. Cells were treated for 72 h, and total RNAs were iso-
lated using the Direct-zol RNA MiniPrep kit (Zymo Research, Irvine, CA). Reverse transcription was per-
formed using NxGen M-MuLV reverse transcriptase (Lucigen, Middleton, WI), and a stem-loop primer 
5′ -GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACAACC-3′ (IDT, San Diego, CA) 
for miR-34a, and iScript reverse-transcription Supermix (Bio-Rad) for U6. RT-qPCR was performed using quan-
titative RT-PCR Master mix (New England Biolabs) on a CFX96 Touch real-time PCR system (Bio-Rad), as 
described previously24,25. Cells were treated in triplicate and assayed separately. Relative miR-34a levels were 
calculated by using the comparative threshold cycle (Ct) method with the formula 2−∆∆Ct.
Protein isolation and Western blot analysis. Cells were seeded in six-well plates and treated with 4 nM 
tRNA/mir-34a, tRNA/MSA or vehicle, as described above. 72 h post-transfection, cells were harvested with trypsin 
and washed twice with cold PBS. Cell lysates were prepared using RIPA buffer (Rockland Immunochemical 
Inc., Limerick, PA) supplemented with the complete protease inhibitor cocktail (Roche, Nutley, NJ). 
Protein concentrations were quantitated with a BCA Protein Assay Kit (Thermo Fisher Scientific Inc.). Whole 
cell proteins (40 μ g/lane) were separated on a 10% SDS-PAGE gel and electro-transferred onto PVDF membranes 
using Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were incubated with anti-SIRT1 (1:500 dilution; 
H-300; Santa Cruz Biotech Inc., Texas, TX), anti-c-MET (1:200; C-28; Santa Cruz), anti-BCL2 (1:200; N-19; Santa 
Cruz), anti-CDK6 (1:1000; C-21; Santa Cruz), or anti-GAPDH (1:2,000; FL-335; Santa Cruz) rabbit polyclonal 
antibody. The membranes were then blotted with a peroxidase goat anti-rabbit IgG (Jackson ImmunoResearch 
Inc., West Grove, PA), incubated with Clarity Western ECL substrates (Bio-Rad), and visualized with the 
ChemiDoc MP Imaging System (Bio-Rad).
Flow cytometry analyses of cell cycle and apoptosis. Cells were seeded in six-well plates and treated 
with 4 nM tRNA/mir-34a or tRNA/MSA, or vehicle for 72 h. To examine the effects on cell cycle, DNA of the 
cells was stained with PI/RNase Staining Buffer (BD Biosciences, San Jose, CA). To define the impact on apop-
tosis, cells were incubated with Annexin V-FITC conjugate and propidium iodide solution (Trevigen Inc., 
Gaithersburg, MD). Samples were analyzed on a FACScan flow cytometer (BD Biosciences, San Jose, CA), and all 
data were processed by Flowjo (Ashland, OR). Cells were treated in triplicate and assayed separately.
Cell invasion assay. Cells were treated with 4 nM tRNA/mir-34a or tRNA/MSA, or vehicle. After 72 h, 
3 × 104 cells were subjected to invasion assay using the Corning BioCoat Matrigel Invasion Chamber with 8.0 μ 
m PET membrane (Corning, NY) for 24 h. The upper inserts with matrigel coating were then fixed with 10% for-
malin, stained with 0.1% crystal violet, and photographed under an Olympus IX2-UCB microscope (200× mag-
nification). Cells were treated in triplicate and assayed separately. Five fields per insert were photographed. The 
number of cells was counted using Adobe Photoshop’s count tool, and compared between different treatments as 
we described recently50.
Immunofluorescence study on apoptosis and proliferation biomarkers. Cells were seeded onto 
gelatin coated coverslips (Neuvitro Corporation, Vancouver, WA), which were inserted in 6-well plates. Cells 
were then treated with 4 nM tRNA/mir-34a or tRNA/MSA, or vehicle or 72 h. The coverslips were fixed with 10% 
formalin, permeabilized with 0.5% tween-20 (for Caspase-3, located in the cytoplasm) or Triton-X100 (for Ki-67, 
located in the nucleus), and blocked with 1% BSA. After that, coverslips were incubated overnight with a primary 
monoclonal antibody (anti-Caspase-3, #9579S; anti-Ki-67, 9129S; Cell signaling Technology, Beverly, MA), and 
then with a secondary antibody (anti-rabbit IgG Alexa Fluor® 488 Conjugate, #4412; Cell signaling Technology). 
Nucleus was conterstained with DAPI (#8961, Cell signaling Technology). Images were taken with a Zeiss Axio 
Observer.z1 Microscope coupled to a Zeiss LSM 710 Scanning Device (Zeiss, Oberkochen, Germany). Cells were 
treated in triplicate and assayed separately. Caspase-3-positive cells were counted directly under the confocal 
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microscope. The intensity of Ki-67 fluorescence was quantified using the ImageJ software, normalized to the 
number of cells/nuclei, and then compared between different treatments.
Orthotopic osteosarcoma xenograft tumor mouse model. Animal procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) at UC-Davis, and were conducted in accordance with the 
Guide for the Care and Use of Laboratory Animals issued by the National Institutes of Health. Immunodeficient 
athymic nude mice (5- to 6-week old males, J:NU strain) were purchased from The Jackson Laboratory 
(Bar Harbor, ME). Orthotopic OS xenograft tumors were generated using a subperiosteal injection method22,38. 
Briefly, 143B cells (4–6 passages) were harvested and resuspended in PBS to a final concentration of 3 × 107 
cells/ml. 50 μ l of the cell suspension (1.5 × 106 cells) were mixed with 50 μ l of matrigel matrix (BD Biosciences). 
Animals were anesthetized i.p. with ketamine (80 mg/kg) and xylazine (7 mg/kg). 100 μ l of the above prepared 
cell suspension were injected subperiosteally onto the right proximal lateral tibia using a 25 gauge needle (BD 
Biosciences). Gentle pressure was applied onto the injection point with index finger for 10 seconds to prevent the 
mix from oozing out. The injection sites were disinfected afterward.
Therapeutic drug efficacy and safety studies. Tumor size was measured with a caliper, and tumor vol-
ume was calculated using the equation: tumor volume (mm3) = (length + width) (mm) × length (mm) × width 
(mm) × 0.2618)39. On day 9 post-inoculation, 18 mice with similar body weights and tumor sizes (tumor vol-
umes = 69.3 ± 35.4 mm3) were randomly divided into 3 groups. Bioengineered tRNA/mir-34a was formulated 
with in vivo-jetPEI (Polyplus-transfection Inc., New York, NY), and administered i.v. into the mice via tail vein 
(loading dose 50 μ g/mouse on day 9; maintenance dose 25 μ g/mouse/day on days 11, 14, 16, 18, and 21). Control 
mice were treated with the same doses of tRNA/MSA formulated with in vivo-jetPEI or just the vehicle. On 
day 22 post inoculation, all mice were sacrificed and xenograft tumors were dissected and visually compared. 
Tumors were fixed in 10% formalin and subjected to hematoxylin and eosin staining histological examination 
in the Clinical Immunohistochemistry Laboratory at Roswell Park Cancer Institute. In addition, blood sample 
was collected from each mouse, and serum was isolated using a serum separator (BD Biosciences). Mouse blood 
chemistry profiles were determined in the Comparative Pathology Laboratory at UC-Davis.
Statistical analysis. Values were expressed as mean ± SD. Depending upon the groups and variances, data 
were analyzed with one-way or two-way ANOVA with Bonferroni post-tests (GraphPad Prism). Difference was 
considered as significant when P-value was less than 0.05 (P < 0.05).
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